Summary:
A Randomized, Open-label, Parallel, Phase 2a Study to Determine the Tolerability, Pharmacokinetics, and Efficacy of APD371 in Subjects with Crohn’s disease experiencing Abdominal Pain
Qualified Participants Must:
• Have had Crohn's disease for at least 3 months
•
Have chronic moderate to severe abdominal pain
Qualified Participants May Receive:
Transportation options and compensation up to $850 for time and travel may be available.